This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, Canada) and provides an Excel-based forecast model for Crohn's Disease market through 2032.
The analyst estimates Crohn's Disease (CD) drug sales across the 8MM covered in this report will increase from $9.5 billion to $15 billion, at a compound annual growth rate (CAGR) of 4.7%, by the end of the forecast period in 2032. The growth of the market will be driven by the approval and launches of 15 pipeline, generic, and biosimilar therapies.
Major drivers of CD market growth over the forecast period are the:
- The emergence within the market of novel and innovative therapies that provides significant improvement in therapeutic efficacy over current treatments
- Successful legal rulings in favor of pharmaceutical companies over the legality of drug price legislature in the US
- Updated recommendations for the rapid incorporation of newer therapies by healthcare providers
Major barriers that will restrict the growth of the CD market during the forecast period are the:
- Legislature by the US government to reduce drug prices resulting in lower sales in the largest global market
- The emergence of several biosimilar and generic drugs entering the US market
- Disruption of the pharmaceutical supply chain and the production of biologics due to geopolitical events
Major drivers of CD market growth over the forecast period are the:
- The emergence within the market of novel and innovative therapies that provides significant improvement in therapeutic efficacy over current treatments
- The launch of the MK-7240 companion diagnostic test
- Updated recommendations for the rapid incorporation of newer therapies by healthcare providers
- Topline CD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, Japan, and Canada over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global CD therapeutics market. Insightful review of the key industry drivers and barriers.
- Develop business strategies by understanding the trends shaping and driving the global CD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global CD therapeutics market from 2022-2032.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
The analyst estimates Crohn's Disease (CD) drug sales across the 8MM covered in this report will increase from $9.5 billion to $15 billion, at a compound annual growth rate (CAGR) of 4.7%, by the end of the forecast period in 2032. The growth of the market will be driven by the approval and launches of 15 pipeline, generic, and biosimilar therapies.
Major drivers of CD market growth over the forecast period are the:
- The emergence within the market of novel and innovative therapies that provides significant improvement in therapeutic efficacy over current treatments
- Successful legal rulings in favor of pharmaceutical companies over the legality of drug price legislature in the US
- Updated recommendations for the rapid incorporation of newer therapies by healthcare providers
Major barriers that will restrict the growth of the CD market during the forecast period are the:
- Legislature by the US government to reduce drug prices resulting in lower sales in the largest global market
- The emergence of several biosimilar and generic drugs entering the US market
- Disruption of the pharmaceutical supply chain and the production of biologics due to geopolitical events
Key Highlights
- The analyst estimates that sales of drugs in the CD market was approximately $9.5 billion in 2022 in the 8MM. The global CD market is expected to grow to $15.0 billion in 2032, at a Compound Annual Growth Rate (CAGR) of 4.7%.Major drivers of CD market growth over the forecast period are the:
- The emergence within the market of novel and innovative therapies that provides significant improvement in therapeutic efficacy over current treatments
- The launch of the MK-7240 companion diagnostic test
- Updated recommendations for the rapid incorporation of newer therapies by healthcare providers
Scope
- Overview of CD including epidemiology, disease etiology and management.- Topline CD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, Japan, and Canada over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global CD therapeutics market. Insightful review of the key industry drivers and barriers.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.- Develop business strategies by understanding the trends shaping and driving the global CD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global CD therapeutics market from 2022-2032.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Crohn’s Disease: Executive Summary
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
8 R&D Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Current and Future Players
12 Market Outlook
13 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Bristol Myers Squibb
- Janssen
- Lilly
- Merck
- Pfizer
- Takeda
- Telavant
- Teva Pharmaceuticals
- Ventyx Biosciences
